PMID- 11770175
OWN - NLM
STAT- MEDLINE
DCOM- 20020319
LR  - 20151119
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 142
IP  - 46
DP  - 2001 Nov 18
TI  - [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in 
      breast cancer].
PG  - 2563-8
AB  - The HER2 protein is encoded by the HER2/neu gene and it is homologous to the 
      epidermal growth factor receptor. Overexpression of HER2, usually in association 
      with gene amplification, occurs in approximately 25-30% of breast cancers. There 
      are currently several different methods available to evaluate HER2 status, e.g. 
      immunohistochemical (IHC), and fluorescence in situ hybridization (FISH) assays. 
      The HER2 protein is a viable therapeutic target. The humanized anti-HER2 
      monoclonal antibody trastuzumab (Herceptin) has demonstrated activity in clinical 
      trials in women with metastatic breast cancer overexpressing HER2. The mechanisms 
      of the action of this antibody involve disruption of DNA repair and induction of 
      antibody-dependent cellular cytotoxicity. Response rates to the antibody given as 
      a single agents in the treatment of HER2 overexpressing metastatic breast cancer 
      have ranged from 12 to 27%. Patients who received trastuzumab in combination with 
      chemotherapy had a significantly longer time to progression, higher overall 
      survival compared with patients who had received chemotherapy alone. In the 
      treatment of women with HER2 overexpressing tumors an overall response rate of 
      57% for combination trastuzumab plus paclitaxel compared with 25% for paclitaxel 
      alone was found. Trastuzumab has an important role in the treatment of HER2 
      overexpressing metastatic breast cancer. Its place in adjuvant treatment has not 
      been proved up to now. The optimal use of trastuzumab in the treatment of HER2 
      positive advanced breast cancer is under active investigation. Due to the high 
      rate of clinical activity and low incidence of severe toxicity trastuzumab is a 
      very promising drug in the treatment of breast cancer. The author's purpose was 
      to summarize the results of the trials using trastuzumab treatment, and discuss 
      the methods used to determine the HER2 status.
FAU - Dank, M
AU  - Dank M
AD  - Altalanos Orvostudomanyi Kar, Radiologiai es Onkoterapias Klinika, Semmelweis 
      Egyetem, Budapest. dank@radi.sote.hu
LA  - hun
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Rekombinans human anti-HER2 monoklonalis antitest--egy uj celzott terapia az 
      emlorak kezeleseben.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Receptor, ErbB-2/*drug effects
MH  - Trastuzumab
MH  - Treatment Outcome
MH  - Up-Regulation/drug effects
RF  - 50
EDAT- 2002/01/05 10:00
MHDA- 2002/03/20 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/03/20 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
PST - ppublish
SO  - Orv Hetil. 2001 Nov 18;142(46):2563-8.